Metabolic / Weight Loss · 10mg × 10 vials
one shot of this blend hits two different "I'm full" switches in the brain at the same time, so it kills hunger harder and takes off more weight than a GLP-1 like Ozempic does on its own.
Cagrilintide + Semaglutide (the research equivalent of Novo Nordisk's CagriSema) is a fixed-ratio blend of two once-weekly injectable compounds that suppress appetite through two genuinely separate brain circuits, which is why the combination loses noticeably more weight than either drug alone. Semaglutide is a long-acting GLP-1 receptor agonist: an analog of the gut hormone GLP-1 with an albumin-binding fatty-acid side chain that drags its half-life out to about 7 days. It activates GLP-1R in the pancreas (glucose-dependent insulin release, glucagon suppression), the gut (slows gastric emptying so food stays put), and the brain's arcuate nucleus and brainstem appetite centers - this is the "food noise goes quiet" effect. Cagrilintide is a long-acting analog of amylin, the pancreatic hormone co-released with insulin after a meal that tells the brain "you're full." It binds amylin receptors (calcitonin receptor plus RAMP complexes, AMY1/2/3) in the area postrema of the hindbrain - a satiety-and-nausea gate outside the blood-brain barrier - and is engineered to be non-fibrillating and albumin-bound for once-weekly dosing, unlike the older amylin drug pramlintide that had to be dosed three times a day. The reason the two stack so cleanly is that the amylin pathway is mechanistically distinct from GLP-1R: cagrilintide adds satiety through both the homeostatic and the hedonic (food-reward) circuits and further slows gastric emptying, while semaglutide drives hypothalamic appetite suppression and peripheral metabolic effects. Two non-overlapping satiety signals produce roughly additive weight loss, and cagrilintide's amylin arm also helps preserve lean mass while preferentially burning fat. In the REDEFINE 1 Phase 3 trial, the combination hit 20.4% mean body-weight loss at 68 weeks (treatment-policy estimand) versus 14.9% for semaglutide alone and 11.5% for cagrilintide alone, confirming the synergy at scale. In plain language: one shot of this blend hits two different "I'm full" switches in the brain at the same time, so it kills hunger harder and takes off more weight than a GLP-1 like Ozempic does on its own.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
This blend is a legitimate first-line GLP-1 for someone who wants the strongest sema-class result from the start, but the GI side-effect floor is higher than sema alone because you're titrating two appetite drugs at once. The slow 4-week-per-step climb exists precisely to keep nausea manageable. A 5 mg/5 mg vial at 0.25 mg/wk lasts a long runway through the early steps. If a customer has never run any GLP-1, consider starting them on semaglutide solo first and layering cagrilintide later, rather than opening with the full blend - but the blend is fine for motivated starters who accept the titration discipline.
Nausea peaks during weeks 9-16 as both drugs climb - this is the window to slow escalation, eat smaller low-fat meals, and stay hydrated. The cagrilintide arm tends to make the climb a bit smoother than pushing a GLP-1 alone to its ceiling, because total satiety is split across two circuits so neither drug is doing all the work.
Advanced use is about adherence and maintenance, not dose escalation. For customers who plateau at 2.4/2.4 and want more, the move is to add a separate-mechanism compound (5-Amino-1MQ, MOTS-c) rather than push the blend higher. Like all GLP-1s, this is continuous-use, not a cycle.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
, NEJM 2025](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081) - Phase 3, n=3,417, 68 weeks; 20.4% loss (treatment-policy) / 22.7% (trial-product) vs sema 14.9-16.1%, cagri 11.5-11.8%, placebo 2.3-3.0%
Read study ↗Clinical guidelinesREDEFINE 1 and REDEFINE 2 - ACC Journal Scan summary (2025)](https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2025/07/02/14/43/REDEFINE-1-and-REDEFINE-2) - both Phase 3 trial designs and combined results, cardiology-society framing
Read study ↗Clinical guidelinesAmerican Diabetes Association - CagriSema demonstrates significant weight loss (ADA 2025)](https://diabetes.org/newsroom/press-releases/cagrisema-demonstrates-significant-weight-loss-adults-obesity) - ADA 85th Scientific Sessions presentation of the REDEFINE data
Read study ↗Clinical guidelinesNovo Nordisk - CagriSema superior weight loss in obesity/overweight + T2D, REDEFINE 2 (2025)](https://www.globenewswire.com/news-release/2025/03/10/3039539/0/en/Novo-Nordisk-A-S-CagriSema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-the-REDEFINE-2-trial.html) - REDEFINE 2, n=1,206, ~15.7% loss vs 3.1% placebo in T2D population
Read study ↗PubMedCagrilintide lowers bodyweight through brain amylin receptors 1 and 3 (PMC12270663, 2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12270663/) - amylin receptor pharmacology, area postrema mechanism, hedonic-reward action, fat-preferential loss
Read study ↗PubMedCagrilintide: A Long-Acting Amylin Analog for Obesity, Cardiology in Review 2024Lau Phase 2 monotherapy dose-finding, pharmacokinetics, non-fibrillating design
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Nausea is the dominant early complaint - described as worse than sema alone during the climb, then settling once both drugs reach steady dose around week 17. Sunday-night dosing to push peak nausea onto a weekend is a near-universal community tip.
Stronger appetite kill than sema solo: users describe food becoming "boring" plus a hard hunger cut, attributed to the two-circuit hit. Some specifically report cravings (sweets/junk) dropping more than baseline hunger, consistent with cagrilintide's hedonic-reward action.
Injection-site welts: a frequent complaint, traced to the cagrilintide component; aggressive site rotation fixes it for most.
"It's basically prescription CagriSema for less hassle" framing is common - community treats the blend as the research-side equivalent of Novo's Phase 3 product.
Constipation managed with fiber, water, and magnesium; sulfur burps reported but generally lighter than on some pure GLP-1 regimens.
Slowing or pausing a titration step when nausea spikes is the consensus self-management move, rather than powering through.
Route: SubQ
Injection site: abdomen, outer thigh, or back of upper arm; rotate every injection, don't reuse the same spot within 7 days. Injection-site redness is the most-reported AE after nausea, and the cagrilintide component drives most of it.
Storage: refrigerated 36-46°F, ~28-30 days after reconstitution; the cagrilintide component is the freshness-limiting one (GLP-1/amylin blends lose potency faster than sema alone past ~4-6 weeks). Unreconstituted vials refrigerated, sealed.
Notes: Same weekday each week; time of day doesn't matter given the ~7-day half-life, but consistency helps tracking. Many community users dose Sunday evening so peak nausea lands on a weekend. Don't shake - swirl gently, inject the BAC down the inside wall of the vial. Use a fresh U-100 insulin syringe per draw. No fasting requirement. Because the blend is pre-matched, titration is done by drawing a larger volume each step - you never split the two drugs apart.